EFFECT OF INTRAVENOUS ADMINISTRATION OF HUMAN GROWTH HORMONE ON SULPHATION FACTOR ACTIVITY IN SERUM OF HYPOPITUITARY SUBJECTS

1971 ◽  
Vol 66 (3) ◽  
pp. 491-497 ◽  
Author(s):  
Kerstin Hall
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Intravenous Administration ◽  
Human Growth ◽  
Significant Rise ◽  
Mean Difference ◽  
Factor Activity ◽  
The Mean

ABSTRACT Human growth hormone (HGH) administered as an iv injection of 2–4 mg to hypopituitary patients induced a rise in the levels of sulphation factor (SF) in serum. The low basal levels of SF were not changed during the first hour after HGH injection. Not until three hours after injection, when HGH values approached basal values, there was a significant rise in SF. The mean difference of SF at one and at three hours after HGH injection was 0.52 ± 0.11.

Human growth hormone blunts Na2EDTA-induced hypocalcaemia in hyposomatotrophic children

1983 ◽  
Vol 102 (1) ◽  
pp. 11-15
Author(s):  
Allen W. Root ◽  
Gregory E. Duckett ◽  
Margaret Sweetland ◽  
Catherine Livingston ◽  
Edward O. Reiter
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Ionized Calcium ◽  
Total Calcium ◽  
The Mean ◽  
Pre Treatment ◽  
Basal Concentration ◽  
Immunoreactive Parathyroid Hormone ◽  
Ethylenediamine Tetraacetate

Abstract. An infusion of disodium ethylenediamine tetraacetate (Na2EDTA) (0.13 mmol/kg for 2 h) was administered to 10 hyposomatotrophic children prior to and after 6 and 12 months of treatment with human growth hormone (hGH). Total and ionized calcium and immunoreactive parathyroid hormone (iPTH) concentrations were determined. Mean basal total and ionized calcium concentrations did not change during the year of treatment with hGH. The nadir concentrations of total and ionized calcium increased progressively during hGH administration and after 12 months were significantly increased over pre-treatment values (total calcium: pre-treatment 1.85 ± 0.32 (sd) mmol/l, + 12 months 2.10 ± 0.15, P < 0.01; ionized calcium: pre-treatment 0.55 ± 0.31 mmol/l, + 12 months 0.78 ± 0.14, P < 0.05). The mean basal concentration of iPTH increased slightly after 12 months of hGH administration (pre-treatment 72 ± 18 pg/ml, + 12 months 106 ± 71, P < 0.05), but Na2EDTA-evoked secretion of iPTH was not significant altered by hGH.

STIMULATION OF IMMUNOREACTIVE INSULIN AND HUMAN GROWTH HORMONE RELEASE BY ADMINISTRATION OF ARGININE IN PATIENTS WITH DIABETIC RETINOPATHY

1972 ◽  
Vol 70 (4) ◽  
pp. 719-730 ◽  
Author(s):  
W. Waldhäusl
Keyword(s):  
Growth Hormone ◽  
Diabetic Retinopathy ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Immunoreactive Insulin ◽  
Insulinogenic Index ◽  
Hormone Release ◽  
Arginine Hydrochloride ◽  
The Mean ◽  
Secretory Capacity

ABSTRACT The effect of arginine hydrochloride (30 g), given twice at 90 min intervals, on the release of immunoreactive insulin and of human growth hormone was studied in healthy subjects (HS), in diabetics without and with various degrees of retinopathy and in acromegalics. The insulinogenic index estimated by the ratio of μU IRI per ml/mg per 100 ml of blood glucose was maximal in HS after the first administration of arginine. It was highest in acromegalics and diminished in all the diabetic subjects. The release of human growth hormone as estimated by the mean sum of increments above the basal levels (x̄ + sem) during period I and II was 80.2±15 ng/ml and 59.0±18 ng/ml in HS (n = 7), 38±8.6 ng/ml and 36±16.3 ng/ml in diabetics without retinopathy (n = 9), 4.2±0.4 ng/ml and 19±7 ng/ml in insulin treated diabetics with retinopathy (n = 9), and 22.7±10.7 ng/ml and 46±10.5 ng/ml in orally treated diabetics with retinopathy (n = 7). Patients suffering from proliferative retinopathy (n = 9) exhibited values of 32.8±10.6 ng/ml during period I and 43.5±10.6 ng/ml during period II. The secretory response of HGH to arginine in acromegalics (n = 6) was not significant. The data reported suggest an impaired secretory capacity for the release of human growth hormone to the administration of arginine in patients with diabetic retinopathy. The observations do not support the hypothesis that an exaggerated release of HGH plays a role in the development of diabetic retinopathy.

SULPHATION FACTOR ACTIVITY AND GROWTH RATE DURING LONG-TERM TREATMENT OF PATIENTS WITH PITUITARY DWARFISM WITH HUMAN GROWTH HORMONE

1972 ◽  
Vol 69 (3) ◽  
pp. 417-433 ◽  
Author(s):  
Kerstin Hall ◽  
Patrick Olin
Keyword(s):  
Growth Hormone ◽  
Growth Rate ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Factor Activity ◽  
Duration Of Treatment ◽  
Pituitary Dwarfism ◽  
Long Term Treatment

ABSTRACT Twenty patients with pituitary dwarfism were treated for nine months to 2½ years with human growth hormone (HGH) prepared according to Roos et al. (1963). Eleven of them had previously been given other HGH preparations for one to five years. During the first two years of treatment with HGH in a dose of 0.2 mg (0.4 IU) and 0.3 mg (0.6 IU) per kg body weight per week, the increase in growth rate was two- to threefold, and three- to fivefold, respectively. Long-termed treatment with HGH was accompanied by a decreasing ability of the hormone to stimulate growth. Cortisone acetate, in replacement doses, had no influence on this growth rate. During the present study only one of the 20 patients developed antibodies to HGH. The levels of sulphation factor (SF) activity in serum were low before treatment and increased significantly during treatment with HGH. There was a linear relationship between the SF activity in the serum and the slope of the growth carves. Both increased with the dose of HGH administered but decreased with duration of treatment.

EFFECTS OF SHORT TERM ADMINISTRATION OF PHYSIOLOGICAL DOSES OF HUMAN GROWTH HORMONE IN THREE PATIENTS WITH TURNER'S SYNDROME

1964 ◽  
Vol 46 (3) ◽  
pp. 451-464 ◽  
Author(s):  
S. Almqvist ◽  
Kerstin Hall ◽  
S. Lindstedt ◽  
J. Lindsten ◽  
R. Luft ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Urinary Excretion ◽  
Human Growth Hormone ◽  
Sex Chromosome ◽  
Human Growth ◽  
Hormone Treatment ◽  
Turner's Syndrome ◽  
Factor Activity ◽  
Turner’S Syndrome ◽  
Short Term

ABSTRACT The effect of apparently physiological doses of human growth hormone was investigated in three patients with Turner's syndrome in short term metabolic balance studies. The subjects presented an abnormal sex chromosome constitution and an increased level of sulphation factor activity in serum. Two dose levels of hormone were used, and there appeared an anabolic response to both. No correlation with dose was obtained for any of the parameters used except for urinary magnesium, where the retention was greater with the higher dose. The sulphation factor activity of serum increased during hormone administration in the one case studied in this respect. The urinary excretion of hydroxyproline was within the normal range in the two patients studied in this respect, and was not altered by growth hormone. All patients had an increased urinary excretion of creatine which at present cannot be explained. The creatinuria diminished during growth hormone treatment. The mechanism behind the retarded growth is discussed. It is suggested that a major factor might be a defect in the center for linear growth, i. e. the epiphyses that would make these less responsive to all the factors normally stimulating the growth processes in the epiphyseal zones.

EFFECTS OF HUMAN GROWTH HORMONE ON THE SECRETION OF RAT GROWTH HORMONE

1980 ◽  
Vol 86 (1) ◽  
pp. 165-169 ◽  
Author(s):  
J. O. WILLOUGHBY ◽  
MARGARET MENADUE ◽  
P. ZEEGERS ◽  
P. H. WISE ◽  
J. R. OLIVER
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Male Rats ◽  
Mean Frequency ◽  
Rat Growth ◽  
The Mean

Human growth hormone (hGH) was administered to chronically cannulated male rats and its effect upon the physiological secretory patterns of rat growth hormone (rGH) and prolactin were observed. In comparison with injected control animals, a reduction in the size of spontaneous secretory bursts of rGH was apparent when hormone concentrations were compared 3–6 h after administration of hGH (136·27 ± 27·31 (s.e.m.) v. 76·22 ± 20·98 ng/ml respectively). However, the mean frequency of secretory episodes of rGH was unaltered. It is therefore postulated that endogenous rGH may modulate the amplitude but not the rhythmicity of secretory episodes of rGH.

OBSERVATIONS ON A HAEMAGGLUTINATION—INHIBITION TECHNIQUE FOR ESTIMATING HUMAN GROWTH HORMONE

1963 ◽  
Vol 26 (2) ◽  
pp. 219-231 ◽  
Author(s):  
P. J. O'CONNOR ◽  
L. G. SKINNER
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Haemagglutination Inhibition ◽  
Human Growth ◽  
Mean Value ◽  
Normal Adult ◽  
Adult Human ◽  
Human Sera ◽  
The Mean ◽  
Inhibition Technique

SUMMARY The haemagglutination—inhibition technique has been examined as a method of estimating human growth hormone (HGH) and the need for rigid standardization of the procedures involved is stressed. Examination of antisera to a Raben type preparation by immunodiffusion and haemagglutination—inhibition procedures showed the presence of antibodies to albumin and γ-globulin as well as to HGH. The presence of these contaminating antibodies did not appear to interfere with the endpoints obtained in the haemagglutination—inhibition reactions. Within its limitations the technique has been found suitable for the assay of solutions of purified HGH. The mean level of HGH in six normal adult human sera was estimated as 261 ± 23·6 μg./l. (± s.e.) which is similar to the values obtained by other workers, but the validity of this mean value is questioned.

LIPOLYTIC ACTIVITY OF ENZYME DIGESTED HUMAN GROWTH HORMONE

1965 ◽  
Vol 49 (3_Suppl) ◽  
pp. S143
Author(s):  
Zvi Laron ◽  
Avivah Kowadlo-Silbergeld
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Lipolytic Activity ◽  
Human Growth
Sign in / Sign up

Export Citation Format

Share Document